Activating FLT3 mutations in CD117/KIT+ T-cell acute lymphoblastic leukemias

被引:69
作者
Paietta, E
Ferrando, AA
Neuberg, D
Bennett, JM
Racevskis, J
Lazarus, H
Dewald, G
Rowe, JM
Wiernik, PH
Tallman, MS
Look, AT
机构
[1] New York Med Coll, Our Lady Mercy Canc Ctr, Immunol Lab, Bronx, NY 10466 USA
[2] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA
[3] Dana Farber Canc Inst, Ctr Stat, ECOG, Boston, MA 02115 USA
[4] Univ Rochester, Rochester, NY USA
[5] Case Western Reserve Univ, Ireland Canc Ctr, Cleveland, OH 44106 USA
[6] Mayo Clin, Rochester, MN USA
[7] Rambam Med Ctr, Haifa, Israel
[8] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
[9] Eastern Cooperat Oncol Grp, Boston, MA USA
关键词
D O I
10.1182/blood-2004-01-0168
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Activating FLT3 mutations are the most common genetic aberrations in acute myeloid leukemia (AML), resulting in the constitutive activation of this receptor tyrosine kinase (RTK), but such mutations are rarely found in acute lymphoblastic leukemia (ALL). Here we describe a unique subset of de novo adult T-cell ALL (T-ALL) cases that coexpress CD117/ KIT and cytoplasmic CD3 (CD117/KIT+ ALL). Activating mutations in the FLT3 RTK gene were found in each of 3 CD117/ KIT+ cases that were analyzed, but not in 52 other adult T-ALL samples from the same series that lacked CD117/KIT expression. Our results indicate the need for clinical trials to test the efficacy of drugs that inhibit the FLT3 RTK in this subset of patients with T-ALL. (C) 2004 by The American Society of Hematology.
引用
收藏
页码:558 / 560
页数:3
相关论文
共 21 条
[1]   Inhibition of FLT3 in MLL: Validation of a therapeutic target identified by gene expression based classification [J].
Armstrong, SA ;
Kung, AL ;
Mabon, ME ;
Silverman, LB ;
Stam, RW ;
Den Boer, ML ;
Pieters, R ;
Kersey, JH ;
Sallan, SE ;
Fletcher, JA ;
Golub, TR ;
Griffin, JD ;
Korsmeyer, SJ .
CANCER CELL, 2003, 3 (02) :173-183
[2]   Analysis of TCR, pTα, and RAG-1 in T-acute lymphoblastic leukemias improves understanding of early human T-lymphoid lineage commitment [J].
Asnafi, V ;
Beldjord, K ;
Boulanger, E ;
Comba, B ;
Le Tutour, P ;
Estienne, MH ;
Davi, F ;
Landman-Parker, J ;
Quartier, P ;
Buzyn, A ;
Delabesse, E ;
Valensi, F ;
Macintyre, E .
BLOOD, 2003, 101 (07) :2693-2703
[3]  
Bertho JM, 2000, SCAND J IMMUNOL, V52, P53
[4]   Stem cell factor and hematopoiesis [J].
Broudy, VC .
BLOOD, 1997, 90 (04) :1345-1364
[5]   Expression of the c-kit (CD117) molecule in normal and malignant hematopoiesis [J].
Escribano, L ;
Ocqueteau, M ;
Almeida, J ;
Orfao, A ;
San Miguel, JF .
LEUKEMIA & LYMPHOMA, 1998, 30 (5-6) :459-466
[6]   Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias:: dominance of HOX dysregulation [J].
Ferrando, AA ;
Armstrong, SA ;
Neuberg, DS ;
Sallan, SE ;
Silverman, LB ;
Korsmeyer, SJ ;
Look, AT .
BLOOD, 2003, 102 (01) :262-268
[7]   Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia [J].
Ferrando, AA ;
Neuberg, DS ;
Staunton, J ;
Loh, ML ;
Huard, C ;
Raimondi, SC ;
Behm, FG ;
Pui, CH ;
Downing, JR ;
Gilliland, DG ;
Lander, ES ;
Golub, TR ;
Look, AT .
CANCER CELL, 2002, 1 (01) :75-87
[8]   The roles of FLT3 in hematopoiesis and leukemia [J].
Gilliland, DG ;
Griffin, JD .
BLOOD, 2002, 100 (05) :1532-1542
[9]  
Jaffe E.S., 2001, PATHOLOGY GENETICS T, V3
[10]   FLT3: ITDoes matter in leukemia [J].
Levis, M ;
Small, D .
LEUKEMIA, 2003, 17 (09) :1738-1752